HK1207981A1 - 治療和預防金黃色葡萄球菌感染和相關病狀的方法 - Google Patents

治療和預防金黃色葡萄球菌感染和相關病狀的方法

Info

Publication number
HK1207981A1
HK1207981A1 HK15108668.7A HK15108668A HK1207981A1 HK 1207981 A1 HK1207981 A1 HK 1207981A1 HK 15108668 A HK15108668 A HK 15108668A HK 1207981 A1 HK1207981 A1 HK 1207981A1
Authority
HK
Hong Kong
Prior art keywords
treating
methods
staphylococcus aureus
associated conditions
aureus infections
Prior art date
Application number
HK15108668.7A
Other languages
English (en)
Inventor
Victor J Torres
Ashley L Dumont
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of HK1207981A1 publication Critical patent/HK1207981A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
HK15108668.7A 2012-05-02 2015-09-04 治療和預防金黃色葡萄球菌感染和相關病狀的方法 HK1207981A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641543P 2012-05-02 2012-05-02
PCT/US2013/032436 WO2013165613A1 (en) 2012-05-02 2013-03-15 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Publications (1)

Publication Number Publication Date
HK1207981A1 true HK1207981A1 (zh) 2016-02-19

Family

ID=49514732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108668.7A HK1207981A1 (zh) 2012-05-02 2015-09-04 治療和預防金黃色葡萄球菌感染和相關病狀的方法

Country Status (9)

Country Link
US (1) US9657103B2 (zh)
EP (1) EP2844287A4 (zh)
JP (1) JP2015517463A (zh)
CN (1) CN104428000A (zh)
AU (1) AU2013257161B2 (zh)
CA (1) CA2871152A1 (zh)
HK (1) HK1207981A1 (zh)
IL (1) IL235284A0 (zh)
WO (1) WO2013165613A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014187746A2 (en) * 2013-05-21 2014-11-27 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
US11421021B2 (en) * 2017-06-13 2022-08-23 Integrated Biotherapeutic Vaccines, Inc. Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
EP3947419A4 (en) * 2019-04-01 2023-05-24 Rush University Medical Center REAGENTS AND ASSAYS USING MODIFIED INTEGRIND DOMAINS
CN114437187B (zh) * 2022-02-09 2023-06-20 淮北师范大学 一种细菌素Bacin A4及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US20030162956A1 (en) * 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
EP1311282A4 (en) * 2000-07-31 2005-07-13 Gen Hospital Corp HIGH AFFINIT INT-GRIN POLYPEPTIDES AND USES THEREOF
EP1543111A4 (en) * 2002-08-28 2006-09-13 Univ Florida NEUROGENESIS FROM HEPATIC STEM CELLS
JP2006094701A (ja) * 2002-09-17 2006-04-13 Chugai Pharmaceut Co Ltd ７ｆ４遺伝子トランスジェニック動物
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
RU2418856C2 (ru) * 2005-02-24 2011-05-20 Дзе Скриппс Рисерч Инститьют Изолированные популяции миелоидоподобных клеток костного мозга и способы лечения с ними
JP5250810B2 (ja) * 2006-05-31 2013-07-31 公益財団法人ヒューマンサイエンス振興財団 ユートロフィン遺伝子発現増強物質のスクリーニング
JP2008220174A (ja) * 2007-03-08 2008-09-25 Tokyoto Igaku Kenkyu Kiko 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
RU2565539C2 (ru) * 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
EP2566519B1 (en) 2010-05-05 2016-09-07 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CA2839558A1 (en) * 2011-06-19 2012-12-27 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
NZ764564A (en) 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions

Also Published As

Publication number Publication date
US20150132310A1 (en) 2015-05-14
CN104428000A (zh) 2015-03-18
AU2013257161A1 (en) 2014-11-20
AU2013257161B2 (en) 2017-11-09
CA2871152A1 (en) 2013-11-07
EP2844287A1 (en) 2015-03-11
JP2015517463A (ja) 2015-06-22
IL235284A0 (en) 2014-12-31
US9657103B2 (en) 2017-05-23
EP2844287A4 (en) 2016-01-27
WO2013165613A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
IL258886A (en) Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions
HK1216389A1 (zh) 治療局部微生物感染的方法
HK1225649A1 (zh) 用於治療細菌性感染的化合物和方法
IL248959A0 (en) Preparations and methods for the treatment and prevention of staphylococcus aureus infections
EP2991968A4 (en) Compounds and methods of treating infections
HK1215537A1 (zh) 抗微生物聚醯胺組合物和乳腺炎治療
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
HK1218293A1 (zh) 治療細菌感染的化合物和方法
HK1207981A1 (zh) 治療和預防金黃色葡萄球菌感染和相關病狀的方法
ZA201503474B (en) Compositions and methods for treating bacterial infections
HK1206203A1 (zh) 飛燕草色素對抗金黃色葡萄球菌的應用
IL241249A0 (en) Antisense molecules for the treatment of Staphylococcus aureus infection
IL241226A0 (en) Antisense molecules for the treatment of Staphylococcus aureus infection
HK1212619A1 (zh) 眼部感染的治療或預防方法
AU2013901516A0 (en) Compounds and Methods of Treating Infections
AU2013902497A0 (en) Treatment and prevention of mastitis
AU2013901517A0 (en) Methods of Treating Bacterial Infections